(Q46110645)

19 December 2017

title

Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia (English)

1 reference

19 December 2017

main subject

schizophrenia

0 references

randomized experiment

1 reference

C Bushe

1

1 reference

19 December 2017

J Sniadecki

series ordinal

2

1 reference

19 December 2017

A J Bradley

series ordinal

3

1 reference

19 December 2017

V Poole Hoffmann

series ordinal

4

1 reference

19 December 2017

language of work or name

English

0 references

publication date

24 February 2009

1 reference

19 December 2017

Journal of Psychopharmacology

published in

1 reference

19 December 2017

volume

24

1 reference

19 December 2017

issue

7

1 reference

19 December 2017

page(s)

1001-1009

1 reference

19 December 2017

Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women

uses

randomized experiment

0 references

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

A review of the association between antipsychotic use and hyperprolactinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

A meta-analysis of the efficacy of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Weight change with atypical antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Adverse effects of prolactin in rodents and humans: breast and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Schizophrenia and increased risks of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Risk of hip fracture in patients with a history of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Long-term maintenance of weight loss in patients with severe mental illness through a behavioural treatment programme in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

A well-being programme in severe mental illness. Reducing risk for physical ill-health: a post-programme service evaluation at 2 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

A well-being programme in severe mental illness. Baseline findings in a UK cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Atypical antipsychotics and pituitary tumors: a pharmacovigilance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Plasma prolactin concentrations and risk of postmenopausal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

Prevention of cardiovascular disease in clinical practice: The Joint British Societies' (JBS 2) guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108101783

21 January 2018

Identifiers

DOI

10.1177/0269881108101783

1 reference

19 December 2017

PubMed ID

19240085

1 reference

19 December 2017